Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,436 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | recruiting | Phase 4 | 60 | AstraZenecaINDUSTRY | 6 | Sep 24, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT07044687 |
| recruiting |
| Phase 4 |
| 100 |
| AbbVieINDUSTRY |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07773909 | Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy | completed | Phase 4 | 24 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04846855 | Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population(RATAPED) | completed | Phase 4 | 100 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06035757 | The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery | completed | Phase 4 | 76 | Konkuk University Medical CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06289673 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | recruiting | Phase 4 | 850 | St. Jude Children's Research HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06370000 | Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality(REMAIN1) | recruiting | Phase 4 | 12 | Virginia Commonwealth UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | recruiting | Phase 4 | 787 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT07320534 | Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase | not yet recruiting | Phase 4 | 124 | Gadjah Mada UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05687032 | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 4 | 44 | PfizerINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT07016165 | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | recruiting | Phase 4 | 120 | Gadjah Mada UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05071482 | Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL | terminated | Phase 4 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06918054 | Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia | recruiting | Phase 4 | 42 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06918080 | Hepatoprotective Measures for Children at High Risk of NAFLD | active not recruiting | Phase 4 | 200 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06571825 | RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR | recruiting | Phase 4 | 118 | He HuangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT03043430 | Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients | terminated | Phase 4 | 10 | Brooke Army Medical CenterFED | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05316831 | Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia | completed | Phase 4 | 77 | Region Örebro CountyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT00198978 | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 4 | 377 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00199056 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) | completed | Phase 4 | 225 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00199095 | Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia | completed | Phase 4 | 40 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00199069 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) | completed | Phase 4 | 720 | Goethe UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05634915 | Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation | unknown | Phase 4 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03318393 | Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO | completed | Phase 4 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05682131 | South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol(SCCCG-R-ALL) | recruiting | Phase 4 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05611086 | N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia | terminated | Phase 4 | 16 | Teny Tjitra SariOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia(LABMI) | terminated | Phase 4 | 119 | University Hospital, AngersOTHER_GOV | 1 | Oct 3, 2022 | clinicaltrials |
| NCT00199082 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | completed | Phase 4 | 650 | Nicola GoekbugetOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT00198991 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) | completed | Phase 4 | 1,883 | Goethe UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04155411 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | unknown | Phase 4 | 65 | Shenzhen Second People's HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03988205 | Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia | terminated | Phase 4 | 3 | Medical College of WisconsinOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT02447718 | Vaccinating Children After Chemotherapy | completed | Phase 4 | 156 | Canadian Immunization Research NetworkNETWORK | 1 | Jun 24, 2022 | clinicaltrials |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | completed | Phase 4 | 176 | South China Children's Leukemia GroupOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials